Cannara Biotech Stock Performance
| LOVFF Stock | USD 0.52 0.09 20.93% |
The firm shows a Beta (market volatility) of -1.27, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Cannara Biotech are expected to decrease by larger amounts. On the other hand, during market turmoil, Cannara Biotech is expected to outperform it. At this point, Cannara Biotech has a negative expected return of -0.0035%. Please make sure to confirm Cannara Biotech's treynor ratio, kurtosis, period momentum indicator, as well as the relationship between the downside variance and day median price , to decide if Cannara Biotech performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Cannara Biotech has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable technical and fundamental indicators, Cannara Biotech is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 8.2 M | |
| Total Cashflows From Investing Activities | -15.3 M |
Cannara |
Cannara Biotech Relative Risk vs. Return Landscape
If you would invest 58.00 in Cannara Biotech on August 28, 2024 and sell it today you would lose (6.00) from holding Cannara Biotech or give up 10.34% of portfolio value over 90 days. Cannara Biotech is currently producing negative expected returns and takes up 5.8045% volatility of returns over 90 trading days. Put another way, 51% of traded otc stocks are less volatile than Cannara, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Cannara Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cannara Biotech's investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Cannara Biotech, and traders can use it to determine the average amount a Cannara Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -6.0E-4
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | LOVFF |
Estimated Market Risk
| 5.8 actual daily | 51 51% of assets are less volatile |
Expected Return
| 0.0 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Cannara Biotech is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cannara Biotech by adding Cannara Biotech to a well-diversified portfolio.
Cannara Biotech Fundamentals Growth
Cannara OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Cannara Biotech, and Cannara Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cannara OTC Stock performance.
| Return On Equity | 0.0434 | |||
| Return On Asset | 0.0327 | |||
| Profit Margin | 0.07 % | |||
| Operating Margin | 0.15 % | |||
| Current Valuation | 94.03 M | |||
| Shares Outstanding | 877.48 M | |||
| Price To Earning | 85.00 X | |||
| Price To Book | 1.37 X | |||
| Price To Sales | 1.81 X | |||
| Revenue | 35.84 M | |||
| EBITDA | 8.14 M | |||
| Cash And Equivalents | 3.88 M | |||
| Total Debt | 46.19 M | |||
| Debt To Equity | 0.49 % | |||
| Book Value Per Share | 0.08 X | |||
| Cash Flow From Operations | (6.08 M) | |||
| Earnings Per Share | 0.15 X | |||
| Total Asset | 125.62 M | |||
About Cannara Biotech Performance
By analyzing Cannara Biotech's fundamental ratios, stakeholders can gain valuable insights into Cannara Biotech's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Cannara Biotech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Cannara Biotech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-infused products in Canada. The company was incorporated in 2017 and is headquartered in Saint-Laurent, Canada. Cannara Biotech is traded on OTC Exchange in the United States.Things to note about Cannara Biotech performance evaluation
Checking the ongoing alerts about Cannara Biotech for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Cannara Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cannara Biotech generated a negative expected return over the last 90 days | |
| Cannara Biotech has high historical volatility and very poor performance | |
| Cannara Biotech has some characteristics of a very speculative penny stock | |
| Cannara Biotech has accumulated about 3.88 M in cash with (6.08 M) of positive cash flow from operations. | |
| Roughly 48.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Cannara Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cannara Biotech's stock is overvalued or undervalued compared to its peers.
- Examining Cannara Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cannara Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cannara Biotech's management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Cannara Biotech's otc stock. These opinions can provide insight into Cannara Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Cannara OTC Stock analysis
When running Cannara Biotech's price analysis, check to measure Cannara Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cannara Biotech is operating at the current time. Most of Cannara Biotech's value examination focuses on studying past and present price action to predict the probability of Cannara Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cannara Biotech's price. Additionally, you may evaluate how the addition of Cannara Biotech to your portfolios can decrease your overall portfolio volatility.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |